Alexandra and Niamh presenting their #glioblastoma #highgradeglioma #noveltargets research at BNS Annual Meeting 2025 #PhD #proudPI @blizardinstitute.bsky.social @qmulfmd.bsky.social @braintumourrsch.bsky.social
January 30, 2025 at 11:08 AM
Alexandra and Niamh presenting their #glioblastoma #highgradeglioma #noveltargets research at BNS Annual Meeting 2025 #PhD #proudPI @blizardinstitute.bsky.social @qmulfmd.bsky.social @braintumourrsch.bsky.social
New from our lab: More evidence that ion channels play a key role in high-grade glioma and represent promising therapeutic targets.
🔗 link.springer.com/article/10.1...
🔗 academic.oup.com/neuro-oncolo...
#highgradeglioma #ionchannel #braincancer
🔗 link.springer.com/article/10.1...
🔗 academic.oup.com/neuro-oncolo...
#highgradeglioma #ionchannel #braincancer
Pharmacological targeting and characterization of Voltage-Gated Sodium Channels (VGSCs) expressed in the high-grade glioma microenvironment - BMC Cancer
BMC Cancer - High-grade glioma (HGG) cells reactivate neurodevelopmental programs regulated by ion channels to drive tumor progression. The activity of voltage-gated sodium channels (VGSCs) is...
link.springer.com
December 3, 2025 at 11:42 PM
New from our lab: More evidence that ion channels play a key role in high-grade glioma and represent promising therapeutic targets.
🔗 link.springer.com/article/10.1...
🔗 academic.oup.com/neuro-oncolo...
#highgradeglioma #ionchannel #braincancer
🔗 link.springer.com/article/10.1...
🔗 academic.oup.com/neuro-oncolo...
#highgradeglioma #ionchannel #braincancer
🧠🧬 Intranasal NEO100 met its primary end point in patients with recurrent IDH1-mutant high-grade glioma.
Read more ➡️ www.onclive.com/view/intrana...
#BrainCancer #Glioma #HighGradeGlioma #IDH1 #NeuroOncology #DrugDevelopment #Oncology
Read more ➡️ www.onclive.com/view/intrana...
#BrainCancer #Glioma #HighGradeGlioma #IDH1 #NeuroOncology #DrugDevelopment #Oncology
Intranasal NEO100 Meets Primary End Point in Recurrent IDH1-Mutant High-Grade Glioma | OncLive
Topline phase 2a data showed a 48.9% six-month progression-free survival rate with intranasal NEO100 in previously treated IDH1-mutant glioma.
www.onclive.com
August 12, 2026 at 7:54 PM
🧠🧬 Intranasal NEO100 met its primary end point in patients with recurrent IDH1-mutant high-grade glioma.
Read more ➡️ www.onclive.com/view/intrana...
#BrainCancer #Glioma #HighGradeGlioma #IDH1 #NeuroOncology #DrugDevelopment #Oncology
Read more ➡️ www.onclive.com/view/intrana...
#BrainCancer #Glioma #HighGradeGlioma #IDH1 #NeuroOncology #DrugDevelopment #Oncology